NBBK:NASDAQNB Bancorp, Inc. Analysis
Data as of 2026-05-19 - not real-time
$19.47
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
NB Bancorp is trading well below its discounted cash‑flow estimate, suggesting a sizable valuation gap. The price‑to‑earnings multiple sits beneath the sector average, reinforcing the cheapness perception. A modest dividend yield combined with a low payout ratio points to sustainable cash returns. Revenue growth remains robust, driven by strong loan and deposit activity in its core Massachusetts market. Operating margins are healthy, and return on equity, while modest, is positive. Technicals show the short‑term moving average marginally above the mid‑term average, while the MACD has turned bearish and volume is on a downtrend, indicating near‑term pressure.
Recent earnings missed consensus estimates, adding short‑term downside pressure. However, a board director’s sizable share purchase after the price dip signals insider confidence. Analyst coverage is limited, but the consensus target aligns with the current price, implying limited upside from analyst revisions. The stock’s beta below one and lower‑than‑market volatility suggest defensive characteristics. With a modest dividend and a strong cash position relative to debt, the company is well‑positioned to weather sector headwinds. Overall, the combination of valuation upside, growth fundamentals, and defensive risk profile makes the stock attractive for patient investors.
Recent earnings missed consensus estimates, adding short‑term downside pressure. However, a board director’s sizable share purchase after the price dip signals insider confidence. Analyst coverage is limited, but the consensus target aligns with the current price, implying limited upside from analyst revisions. The stock’s beta below one and lower‑than‑market volatility suggest defensive characteristics. With a modest dividend and a strong cash position relative to debt, the company is well‑positioned to weather sector headwinds. Overall, the combination of valuation upside, growth fundamentals, and defensive risk profile makes the stock attractive for patient investors.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- recent earnings miss
- bearish MACD and declining volume
- insider share purchase indicating confidence
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- significant valuation upside to DCF
- strong revenue growth and margins
- sustainable dividend with low payout
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- defensive beta and lower volatility
- robust cash position versus debt
- regional market focus with growth potential
Key Metrics & Analysis
Financial Health
Revenue Growth36.30%
Profit Margin23.31%
P/E Ratio14.2
ROE6.65%
ROA0.84%
P/B Ratio1.0
Op. Cash Flow$78.2M
Industry P/E16.7
Technical Analysis
TrendNeutral
RSI38.3
Support$18.51
Resistance$22.48
MA 20$20.00
MA 50$20.82
MA 200$19.78
MACDBearish
VolumeDecreasing
Fear & Greed Index89.05
Valuation
Fair Value$48.47
Target Price$23.00
Upside/Downside18.13%
GradeUndervalued
TypeGrowth
Dividend Yield1.44%
Risk Assessment
Beta0.73
Volatility39.68%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.